Economic and Clinical Burden of Viral Hepatitis in California: A Population-based Study with Longitudinal Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 May 1

PMID 29708985

Citations 10

Authors

Haesuk Park

Donghak Jeong

Pauline Nguyen

Linda Henry

Joseph Hoang

Yoona Kim

Edward Sheen

Mindie H Nguyen

Affiliations

Soon will be listed here.

Abstract

Background: Economic burden of HBV and HCV infection are trending upwards.

Aims: Compare hepatitis B virus (HBV) and hepatitis C virus (HCV) related hospital admission rates, charges, mortality rates, causes of death in a US population-based study.

Methods: Retrospective cohort analysis of HBV and HCV patients from the California Office of Statewide Health Planning and Development (2006-2013) database.

Results: A total of 23,891 HBV and 148,229 HCV patients were identified. Across the 8-year period, the mean increase for all-cause ($1,863 vs $1,388) and liver-related hospitalization charges ($1,175 vs $675) were significantly higher for the HBV cohort compared to the HCV cohort. HBV patients had significantly higher liver-related hospital charges per person per year than HCV patients after controlling for covariates ($123,239 vs $111,837; p = 0.002). Compared to HCV patients, adjusted mortality hazard ratio was slightly lower in HBV patients (relative risk = 0.96; 95% CI 0.94-0.99). The major causes and places of death were different. The three major causes of death for HBV were: other malignant neoplasms (35%), cardiovascular disease/other circulatory disorders (17%), and liver-related disease (15%) whereas for HCV patients were: liver-related disease (22%), other malignant neoplasms (20%), and cardiovascular disease (16%). Regarding the place of death, 53% of HBV patients and 44% of HCV patients died in hospital inpatient, respectively.

Conclusions: HBV patients incurred higher liver-related hospital charges and higher mean increase for all-cause and liver-related hospitalization charges over the 8-year period compared to HCV patients. HBV patients had slightly lower mortality rate and their major causes and places of death were noticeably different from HCV patients.

Citing Articles

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.

Yuen M, Chuang W, Peng C, Jeng W, Su W, Chang T Clin Mol Hepatol. 2024; 30(3):375-387.

PMID: 38528825 PMC: 11261219. DOI: 10.3350/cmh.2023.0535.

Dietary calcium is inversely associated with hepatitis B virus infection: an analysis of US National Health and Nutrition Examination Survey (NHANES) 2007-2020.

Zhang M, Zhang Y, Jiang S, Hu H, Wang X, Yu F J Health Popul Nutr. 2024; 43(1):38.

PMID: 38449003 PMC: 10916236. DOI: 10.1186/s41043-024-00532-4.

A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B.

Congly S, Syed A, Haylock-Jacobs S, Israelson H, Pinto J, Williams S Can Liver J. 2023; 6(3):305-313.

PMID: 38020196 PMC: 10652987. DOI: 10.3138/canlivj-2022-0043.

Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.

Hofmeister M, Zhong Y, Moorman A, Samuel C, Teshale E, Spradling P Clin Infect Dis. 2023; 77(12):1668-1675.

PMID: 37463305 PMC: 11017377. DOI: 10.1093/cid/ciad425.

Prevalence of Hepatitis B Virus infection in the Gulf Cooperation Council: a systematic review and meta-analysis.

Alali A, Abo-Shehada M BMC Infect Dis. 2022; 22(1):819.

PMID: 36344923 PMC: 9641946. DOI: 10.1186/s12879-022-07806-4.

References

Devaki P, Wong R, Marupakula V, Nangia S, Nguyen L, Ditah I . Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era. Cancer. 2014; 120(11):1725-32. DOI: 10.1002/cncr.28639. View

Cholankeril G, Perumpail R, Hu M, Skowron G, Younossi Z, Ahmed A . Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. Dig Dis Sci. 2016; 61(9):2505-15. DOI: 10.1007/s10620-016-4160-z. View

Tran S, Le A, Zhao C, Hoang J, Yasukawa L, Weber S . Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 2018; 5(1):e000192. PMC: 5873543. DOI: 10.1136/bmjgast-2017-000192. View

Szpakowski J, Tucker L . Causes of death in patients with hepatitis B: a natural history cohort study in the United States. Hepatology. 2012; 58(1):21-30. DOI: 10.1002/hep.26110. View

Amin J, Law M, Bartlett M, Kaldor J, Dore G . Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006; 368(9539):938-45. DOI: 10.1016/S0140-6736(06)69374-4. View

Rajbhandari R, Danford C, Chung R, Ananthakrishnan A . HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease. Aliment Pharmacol Ther. 2015; 41(10):928-38. DOI: 10.1111/apt.13162. View

Sie L, Gatto N, Bancroft E . Hospitalizations due to hepatitis C in Los Angeles County, 2007-2009: case characteristics and factors associated with mortality. J Viral Hepat. 2013; 20(9):628-37. DOI: 10.1111/jvh.12086. View

Lin S, Chang E, So S . Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007; 46(4):1034-40. DOI: 10.1002/hep.21784. View

Montuclard C, Hamza S, Rollot F, Evrard P, Faivre J, Hillon P . Causes of death in people with chronic HBV infection: A population-based cohort study. J Hepatol. 2015; 62(6):1265-71. DOI: 10.1016/j.jhep.2015.01.020. View

10.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

11.

Zingmond D, Ye Z, Ettner S, Liu H . Linking hospital discharge and death records--accuracy and sources of bias. J Clin Epidemiol. 2004; 57(1):21-9. DOI: 10.1016/S0895-4356(03)00250-6. View

12.

Chen C, Yang H . Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011; 26(4):628-38. DOI: 10.1111/j.1440-1746.2011.06695.x. View

13.

Duberg A, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A . Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat. 2008; 15(7):538-50. DOI: 10.1111/j.1365-2893.2008.00982.x. View

14.

Kowdley K, Wang C, Welch S, Roberts H, Brosgart C . Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2011; 56(2):422-33. DOI: 10.1002/hep.24804. View

15.

Kim N, Nguyen P, Dang H, Kumari R, Garcia G, Esquivel C . Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015. Cancer. 2018; 124(12):2588-2598. DOI: 10.1002/cncr.31373. View

16.

Walter S, Thein H, Amin J, Gidding H, Ward K, Law M . Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol. 2010; 54(5):879-86. DOI: 10.1016/j.jhep.2010.08.035. View

17.

Yip B, Wantuck J, Kim L, Wong R, Ahmed A, Garcia G . Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci. 2013; 59(1):192-200. DOI: 10.1007/s10620-013-2948-7. View

18.

Mitchell T, Armstrong G, Hu D, Wasley A, Painter J . Correction: The Increasing Burden of Imported Chronic Hepatitis B - United States, 1974-2008. PLoS One. 2018; 8(3). PMC: 5769802. DOI: 10.1371/annotation/7f73ed17-709e-4d7f-9aae-aab1f4a34985. View

19.

Hajarizadeh B, Grebely J, Dore G . Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013; 10(9):553-62. DOI: 10.1038/nrgastro.2013.107. View

20.

Nguyen L, Nguyen M . Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013; 37(10):921-36. DOI: 10.1111/apt.12300. View